Free Trial

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $8.00 Consensus Price Target from Analysts

AbCellera Biologics logo with Medical background

Key Points

  • AbCellera Biologics Inc. has received a consensus rating of "Buy" from six analysts, including one recommendation for a strong buy, indicating positive investor sentiment.
  • The stock's 12-month average price target is $8.00, reflecting potential for growth despite its current trading price around $4.37.
  • Recent quarterly earnings showed AbCellera Biologics beating estimates with a reported EPS of ($0.12), and a revenue of $17.08 million compared to expectations of $7.55 million.
  • Need better tools to track AbCellera Biologics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has been given a consensus rating of "Buy" by the six ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.00.

ABCL has been the subject of several recent research reports. KeyCorp boosted their target price on shares of AbCellera Biologics from $5.00 to $10.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Wall Street Zen raised AbCellera Biologics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Leerink Partners assumed coverage on AbCellera Biologics in a research report on Monday, July 7th. They issued an "outperform" rating and a $5.00 target price on the stock. Leerink Partnrs raised AbCellera Biologics to a "strong-buy" rating in a research report on Monday, July 7th. Finally, Stifel Nicolaus dropped their target price on AbCellera Biologics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Friday, August 8th.

View Our Latest Analysis on AbCellera Biologics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Stratos Wealth Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at about $27,000. Janney Montgomery Scott LLC bought a new position in AbCellera Biologics during the first quarter valued at about $29,000. AssuredPartners Investment Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at about $34,000. Caitong International Asset Management Co. Ltd bought a new position in AbCellera Biologics during the second quarter valued at about $35,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of AbCellera Biologics in the 4th quarter valued at $40,000. Institutional investors own 61.42% of the company's stock.

AbCellera Biologics Stock Down 2.8%

ABCL stock traded down $0.12 during trading on Wednesday, hitting $4.18. 3,613,750 shares of the company's stock traded hands, compared to its average volume of 5,118,854. AbCellera Biologics has a 52 week low of $1.89 and a 52 week high of $5.82. The stock has a fifty day moving average price of $4.25 and a two-hundred day moving average price of $3.09. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -7.60 and a beta of 0.65.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. AbCellera Biologics had a negative net margin of 511.88% and a negative return on equity of 16.17%. The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $7.55 million. As a group, equities research analysts expect that AbCellera Biologics will post -0.59 EPS for the current fiscal year.

AbCellera Biologics Company Profile

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

See Also

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Should You Invest $1,000 in AbCellera Biologics Right Now?

Before you consider AbCellera Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.

While AbCellera Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines